Pdt Partners, LLC Mersana Therapeutics, Inc. Transaction History

Pdt Partners, LLC

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	SELL	$4.63 - $8.0 $1 Million - $1.74 Million	-216,924 Reduced 89.68%	24,975 $169,000
Q2 2022 Aug 15, 2022	SELL	$2.84 - $5.0 $240,036 - $422,600	-84,520 Reduced 25.89%	241,899 $1.12 Million
Q1 2022 May 16, 2022	BUY	$3.74 - $6.63 $803,161 - $1.42 Million	214,749 Added 192.31%	326,419 $1.3 Million
Q4 2021 Feb 14, 2022	BUY	$5.48 - $9.86 $444,839 - $800,385	81,175 Added 266.19%	111,670 $695,000
Q3 2021 Nov 15, 2021	BUY	$8.56 - $14.47 $261,037 - $441,262	30,495 New	30,495 $288,000

125

116M

233K

457K

Ticker MRSN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,169,296
Market Cap $52.5M
Description
Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...

Get notified when there are updates to the investment portfolio of Pdt Partners, LLC, based on Form 13F filings with the SEC.

Stay updated on Pdt Partners, LLC with notifications on news.